[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amyloid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amyloid":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,86,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100642012","phase-2-a-study-of-donanemab-ly3002813-in-participants-with-early-cognitive-decline-trailblazer-alz-7-100642012",false,"NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)","A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology","Inclusion Criteria:\n\n* Have gradual and progressive cognitive decline for greater than or equal to ( ≥) 6 months.\n* Have least 1 core clinical feature of dementia with Lewy bodies (DLB).\n* Have a score ≥20 on Montreal Cognitive Assessment (MoCA).\n* Meet plasma P-tau217 criteria.\n* Have a cerebrospinal fluid (CSF) result consistent with the presence of brain amyloid pathology.\n* Have a CSF result consistent with the presence of alpha-synuclein pathology.\n* Have at least 1 reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant, and is familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.\n\nExclusion Criteria:\n\n* Have a disease or condition that could interfere with this study or is a current serious or unstable illness.\n* Have, or is suspected to have, a significant neurological disease (other than the studied condition) that affects the central nervous system and may affect the individual's cognition or ability to complete the study.\n* Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence and preventing the completion of the study.\n* Have clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions.\n* Have previously received amyloid-targeting therapy.\n* Active immunization against amyloid-beta.\n* Have a centrally read MRI that does not meet study entry criteria.\n* Have contraindication to MRI or PET scans.\n* Have any contraindication to lumbar puncture.","ALL","55 Years","85 Years",{"count":20,"type":21},350,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.",[27,28,29,30],"Cognitive Dysfunction","Lewy Body Disease","Synucleinopathies","Amyloid",[32,33,34,35,36,37,38,39,27],"Mild Cognitive Impairment","Mild Dementia","Brain Diseases","Nervous System Diseases","Neurodegenerative Diseases","Neurocognitive Disorders","Cognition Disorders","Alzheimer Disease","RECRUITING","2026-08-05",{"date":43,"type":44},"2026-08-06","ACTUAL",{"date":46,"type":44},"2026-05-20",{"date":48,"type":21},"2028-08",{"name":50,"class":51},"Eli Lilly and Company","INDUSTRY",71,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100610813","18fft8-pet-imaging-in-immunoglobulin-light-chain-amyloidosis-100610813","NCT07232459","[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis","Clinical Study of [18F]FT8 PET\u002FCT in Evaluating Amyloidosis","1. Subject Recruitment Participants will be recruited from outpatients and\u002For inpatient populations of the Hematology Department at Tianjin Medical University General Hospital. The principal investigator and collaborating hematologists will ensure consistent application of diagnosis and enrollment criteria based on standardized guidelines. The planned enrollment includes 20 patients with systemic amyloidosis (including cardiac involvement) and 5 healthy volunteers.\n2. Amyloidosis Patients:\n\n2.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult patients (age ≥ 18 years);\n2. Suspected, newly diagnosed, or previously diagnosed with cardiac amyloidosis, with supporting evidence from one or more of the following: cardiac MRI, contrast-enhanced CT, serum biomarkers (e.g., NT-proBNP, Troponin), or histopathological confirmation of amyloidosis.\n3. Scheduled to undergo a clinical Pan-Amyloid PET\u002FCT scan as part of standard care or clinical evaluation.\n4. Able to understand the study procedures and provide written informed consent. 2.2 Exclusion Criteria\n\nSubjects will be excluded based on any of the following:\n\n1. Confirmed non-cardiac amyloidosis or other non-amyloid cardiac pathologies that could confound image interpretation.\n2. Pregnancy or breastfeeding.\n3. Any medical, psychological, or social condition that, in the opinion of the investigator, would compromise the subject's ability to participate fully or complete the study follow-up.\n\n3\\. Healthy Volunteers: 3.1 Inclusion Criteria:\n\nSubjects must meet all of the following criteria:\n\n1. Adult subjects (age ≥ 18 years);\n2. No clinical evidence of active cardiac or systemic disease, as confirmed by medical history review, physical examination, and electrocardiogram (ECG).\n3. Able to understand the study procedures and provide written informed consent. 3.2 Exclusion Criteria:\n\nSubjects will be excluded based on any of the following:\n\n1. History or current diagnosis of any significant cardiac, hepatic, renal, or neurological disorder.\n2. Pregnancy or breastfeeding.\n3. Any condition that, in the opinion of the investigator, could pose an increased risk from the study procedure or interfere with the interpretation of study data.",true,"18 Years",{"count":63,"type":21},25,"7 Days","OBSERVATIONAL","\\[18F\\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\\[18F\\]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid. By comparing its diagnostic performance against established clinical methods, including echocardiography, contrast-enhanced MRI, and relevant laboratory tests, this study aims to establish \\[18F\\]FT8 as the basis for a robust PET protocol for the direct visualization and differential diagnosis of AL amyloidosis . The study preimarily evaluates the safety and diagnostic efficacy of \\[18F\\]FT8 PET imaging in human subjects.",[30,68,69,70],"Cardiac Amyloidosis","Amyloidosis","Healthy Subjects",[72,73,74],"PET\u002FCT","Cardiac amyloidosis","immunoglobulin light chain","2025-11-15",{"date":77,"type":44},"2025-11-18",{"date":79,"type":44},"2025-07-21",{"date":81,"type":21},"2028-12-20",{"name":83,"class":84},"Tianjin Medical University","OTHER",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":92,"enrollmentInfo":93,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":85},"100602980","pan-amyloid-petct-in-various-amyloid-related-disease-100602980","NCT07130565","Pan-Amyloid PET\u002FCT in Various Amyloid-Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated cardiac amyloidosis (supporting evidence may include MRI, CT, serum markers and pathology report); (iii) patients who had scheduled Pan-Amyloid PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-CA lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","80 Years",{"count":94,"type":21},500,"To evaluate the potential usefulness of 18F-92\u002FAV45\u002FTPZA\u002FFT8, 11C-PIB positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Pan-Amyloid-related disease patients.",[30,68,69],[72,98,99],"MRI","Pan-Amyloid","2025-08-12",{"date":102,"type":44},"2025-08-19",{"date":104,"type":44},"2023-11-01",{"date":106,"type":21},"2028-11-01",{"name":83,"class":84},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":92,"enrollmentInfo":114,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100571857","beta-amyloid-petct-in-various-a-related-disease-100571857","NCT06725706","Beta Amyloid PET\u002FCT in Various Aβ-Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":94,"type":21},"To evaluate the potential usefulness of 18F-92\u002FAV45, 11C-PIB positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[30,117,36],"Beta-Amyloid",[72,98,117],"2025-06-03",{"date":121,"type":44},"2025-06-04",{"date":123,"type":44},"2012-09-01",{"date":125,"type":21},"2027-12-01",{"name":83,"class":84},3]